Related references
Note: Only part of the references are listed.Design and biological evaluation of tetrahydro-beta-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors
Michel Leonhardt et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Recent advances in the discovery of potent and selective HDAC6 inhibitors
Xiu-Xiu Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities
Shi-Wei Chao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Synthesis and pharmacological screening: Sulfa derivatives of 2-pipecoline-bearing 1,3,4-oxadiazole core
Aziz-ur-Rehman et al.
RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY (2017)
Novel Polyamine-Naphthalene Diimide Conjugates Targeting Histone Deacetylases and DNA for Cancer Phenotype Reprogramming
Alice Pasini et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors
Shuai Tan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Selective Histone Deacetylase Inhibitors with Anticancer Activity
Nan Ma et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
Inside HDACs with more selective HDAC inhibitors
Joelle Roche et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
STRUCTURAL BIOLOGY HDAC6 finally crystal clear
Yanli Liu et al.
NATURE CHEMICAL BIOLOGY (2016)
Synthesis and in vitro antiproliferative activity of new 1,3,4-oxadiazole derivatives possessing sulfonamide moiety
Mahmoud M. Gamal El-Din et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
K. V. Woan et al.
MOLECULAR ONCOLOGY (2015)
An HDAC-Targeted Imaging Probe LBH589-Cy5.5 for Tumor Detection and Therapy Evaluation
Qingqing Meng et al.
MOLECULAR PHARMACEUTICS (2015)
Histone deacetylase 6 in health and disease
Carole Seidel et al.
EPIGENOMICS (2015)
Nucleosome Dancing at the Tempo of Histone Tail Acetylation
Angelique Galvani et al.
GENES (2015)
Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry
Qiao Sun et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Toxicological and metabolic considerations for histone deacetylase inhibitors
Joanna Fraczek et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors
Jay H. Kalin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
Berkley E. Gryder et al.
FUTURE MEDICINAL CHEMISTRY (2012)
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
Yanis Boumber et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
Helen J. Mackay et al.
EUROPEAN JOURNAL OF CANCER (2010)
Creating zinc monkey wrenches in the treatment of epigenetic disorders
Jay Hans Kalin et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
Suresh S. Ramalingam et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors
Alan Kozikowski et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination
C. Boyault et al.
ONCOGENE (2007)
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells
Claudia P. Miller et al.
BLOOD (2007)
Characterization of the two catalytic domains in histone deacetylase 6
H Zou et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Exploring the connection unit in the HDAC inhibitor pharmacophore model: Novel uracil-based hydroxamates
A Mai et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer
T Reid et al.
LUNG CANCER (2004)
Trifluoromethyl ketones as inhibitors of histone deacetylase
RR Frey et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002)
Telomerase activation by histone deacetylase inhibitor in normal cells
M Takakura et al.
NUCLEIC ACIDS RESEARCH (2001)
Share Paper
